Covington's London Office Secures $1 Billion AstraZeneca Mandate
The FTSE 100 company, which has a market capitalisation of £185.9 billion, confirmed the deal in an announcement to the London Stock Exchange on Monday. AstraZeneca was advised by a Covington team led ...
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and ...
AstraZeneca buys cell therapy biotech in up to $1bn deal
AstraZeneca has struck a deal to acquire biotechnology company EsoBiotec for up to $1bn, as the London-listed pharmaceutical ...
AstraZeneca buys cell therapy firm EsoBiotec for $1bn
British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...
Zacks.com on MSN1d
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...
AstraZeneca announces Imfinzi approved in European Union
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
PipelineReview.com1d
Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer
Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...
AstraZeneca (AZN) Gets a Buy from Barclays
Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...
Macmillan Cancer Support12d
Identifying and overcoming barriers to biomarker testing: a new research project from Macmillan Cancer Support and AstraZeneca
Macmillan Cancer Support and AstraZeneca are working in partnership on a new research project to understand the barriers ...